Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00507296 | Skin | SCCIS | positive regulation of inflammatory response | 17/919 | 142/18723 | 6.03e-04 | 9.04e-03 | 17 |
GO:200040111 | Skin | SCCIS | regulation of lymphocyte migration | 10/919 | 61/18723 | 7.14e-04 | 1.02e-02 | 10 |
GO:0051651112 | Skin | SCCIS | maintenance of location in cell | 22/919 | 214/18723 | 8.70e-04 | 1.14e-02 | 22 |
GO:1901216112 | Skin | SCCIS | positive regulation of neuron death | 13/919 | 97/18723 | 8.99e-04 | 1.15e-02 | 13 |
GO:0071356110 | Skin | SCCIS | cellular response to tumor necrosis factor | 23/919 | 229/18723 | 9.25e-04 | 1.18e-02 | 23 |
GO:190162311 | Skin | SCCIS | regulation of lymphocyte chemotaxis | 6/919 | 25/18723 | 1.09e-03 | 1.32e-02 | 6 |
GO:0070098 | Skin | SCCIS | chemokine-mediated signaling pathway | 12/919 | 88/18723 | 1.20e-03 | 1.42e-02 | 12 |
GO:003134913 | Skin | SCCIS | positive regulation of defense response | 26/919 | 278/18723 | 1.28e-03 | 1.49e-02 | 26 |
GO:000181918 | Skin | SCCIS | positive regulation of cytokine production | 38/919 | 467/18723 | 1.63e-03 | 1.81e-02 | 38 |
GO:01401311 | Skin | SCCIS | positive regulation of lymphocyte chemotaxis | 5/919 | 19/18723 | 1.84e-03 | 1.96e-02 | 5 |
GO:00026969 | Skin | SCCIS | positive regulation of leukocyte activation | 34/919 | 409/18723 | 1.97e-03 | 2.06e-02 | 34 |
GO:00421164 | Skin | SCCIS | macrophage activation | 13/919 | 106/18723 | 2.05e-03 | 2.11e-02 | 13 |
GO:003031611 | Skin | SCCIS | osteoclast differentiation | 12/919 | 94/18723 | 2.13e-03 | 2.17e-02 | 12 |
GO:004824613 | Skin | SCCIS | macrophage chemotaxis | 7/919 | 38/18723 | 2.23e-03 | 2.24e-02 | 7 |
GO:0002762 | Skin | SCCIS | negative regulation of myeloid leukocyte differentiation | 8/919 | 49/18723 | 2.46e-03 | 2.40e-02 | 8 |
GO:00430303 | Skin | SCCIS | regulation of macrophage activation | 9/919 | 61/18723 | 2.77e-03 | 2.60e-02 | 9 |
GO:00508678 | Skin | SCCIS | positive regulation of cell activation | 34/919 | 420/18723 | 3.02e-03 | 2.76e-02 | 34 |
GO:0034612110 | Skin | SCCIS | response to tumor necrosis factor | 23/919 | 253/18723 | 3.38e-03 | 3.01e-02 | 23 |
GO:00713474 | Skin | SCCIS | cellular response to interleukin-1 | 13/919 | 113/18723 | 3.61e-03 | 3.18e-02 | 13 |
GO:0051402111 | Skin | SCCIS | neuron apoptotic process | 22/919 | 246/18723 | 4.97e-03 | 4.04e-02 | 22 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0532314 | Cervix | CC | Rheumatoid arthritis | 27/1267 | 93/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 27 |
hsa05417110 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0516319 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0532315 | Cervix | CC | Rheumatoid arthritis | 27/1267 | 93/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 27 |
hsa0541745 | Cervix | N_HPV | Lipid and atherosclerosis | 22/349 | 215/8465 | 7.28e-05 | 7.92e-04 | 6.19e-04 | 22 |
hsa0541755 | Cervix | N_HPV | Lipid and atherosclerosis | 22/349 | 215/8465 | 7.28e-05 | 7.92e-04 | 6.19e-04 | 22 |
hsa0516312 | Liver | Cirrhotic | Human cytomegalovirus infection | 87/2530 | 225/8465 | 2.67e-03 | 1.10e-02 | 6.76e-03 | 87 |
hsa0541722 | Liver | Cirrhotic | Lipid and atherosclerosis | 80/2530 | 215/8465 | 1.18e-02 | 3.81e-02 | 2.35e-02 | 80 |
hsa0532310 | Liver | Cirrhotic | Rheumatoid arthritis | 38/2530 | 93/8465 | 1.52e-02 | 4.57e-02 | 2.82e-02 | 38 |
hsa0516313 | Liver | Cirrhotic | Human cytomegalovirus infection | 87/2530 | 225/8465 | 2.67e-03 | 1.10e-02 | 6.76e-03 | 87 |
hsa0541732 | Liver | Cirrhotic | Lipid and atherosclerosis | 80/2530 | 215/8465 | 1.18e-02 | 3.81e-02 | 2.35e-02 | 80 |
hsa0532311 | Liver | Cirrhotic | Rheumatoid arthritis | 38/2530 | 93/8465 | 1.52e-02 | 4.57e-02 | 2.82e-02 | 38 |
hsa0516322 | Liver | HCC | Human cytomegalovirus infection | 131/4020 | 225/8465 | 6.86e-04 | 2.77e-03 | 1.54e-03 | 131 |
hsa05142 | Liver | HCC | Chagas disease | 61/4020 | 102/8465 | 8.04e-03 | 2.17e-02 | 1.21e-02 | 61 |
hsa0541742 | Liver | HCC | Lipid and atherosclerosis | 118/4020 | 215/8465 | 1.66e-02 | 3.92e-02 | 2.18e-02 | 118 |
hsa0516332 | Liver | HCC | Human cytomegalovirus infection | 131/4020 | 225/8465 | 6.86e-04 | 2.77e-03 | 1.54e-03 | 131 |
hsa051421 | Liver | HCC | Chagas disease | 61/4020 | 102/8465 | 8.04e-03 | 2.17e-02 | 1.21e-02 | 61 |
hsa0541752 | Liver | HCC | Lipid and atherosclerosis | 118/4020 | 215/8465 | 1.66e-02 | 3.92e-02 | 2.18e-02 | 118 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCL3 | SNV | Missense_Mutation | novel | c.123N>T | p.Gln41His | p.Q41H | P10147 | protein_coding | deleterious(0.01) | benign(0.049) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CCL3 | SNV | Missense_Mutation | novel | c.131N>G | p.Gln44Arg | p.Q44R | P10147 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CCL3 | SNV | Missense_Mutation | novel | c.73C>T | p.Leu25Phe | p.L25F | P10147 | protein_coding | tolerated(1) | benign(0.005) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCL3 | SNV | Missense_Mutation | novel | c.178C>T | p.Pro60Ser | p.P60S | P10147 | protein_coding | deleterious(0.02) | possibly_damaging(0.764) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
CCL3 | SNV | Missense_Mutation | rs773703371 | c.203G>A | p.Arg68Gln | p.R68Q | P10147 | protein_coding | deleterious(0) | possibly_damaging(0.842) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
CCL3 | SNV | Missense_Mutation | novel | c.232N>A | p.Glu78Lys | p.E78K | P10147 | protein_coding | deleterious(0.03) | benign(0.021) | TCGA-DD-A73A-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CCL3 | SNV | Missense_Mutation | novel | c.273N>A | p.Ser91Arg | p.S91R | P10147 | protein_coding | deleterious(0) | benign(0.104) | TCGA-18-3414-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
CCL3 | SNV | Missense_Mutation | rs190805628 | c.101G>C | p.Cys34Ser | p.C34S | P10147 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-60-2698-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | mithramycin | PD |
CCL3 | SNV | Missense_Mutation | novel | c.106A>T | p.Ser36Cys | p.S36C | P10147 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-85-7843-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CCL3 | SNV | Missense_Mutation | rs368462880 | c.89N>T | p.Pro30Leu | p.P30L | P10147 | protein_coding | deleterious(0.02) | possibly_damaging(0.751) | TCGA-CQ-6229-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |